Accordingly, therapy with thrombopoietin receptor agonists (TPO-RA), labeled for immune thrombocytopenia and aplastic anemia, has shown some efficacy in thrombocytopenic MDS patients (6). Here, TPO is linked to idiopathic aplastic anemia.